MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Cerus Corp. (CERS) Forges INTERCEPT Platelet Purchase Agreements With Key Blood Component Suppliers 0 comments
    Mar 15, 2013 6:00 PM | about stocks: CERS

    Today, Cerus announced that Austrian blood component supplier TILAK, University Clinics, Regional Hospital Innsbruck (LKI) has signed a one-year purchase agreement for the company's INTERCEPT Blood System for platelets, and Germany's ZIT GmbH Hamburg has signed a four-year purchase agreement.

    One of the largest hospitals in Austria, LKI houses a Central Institute for Blood Transfusion that supplies around 6,000 platelet units each year to the federal state of Tyrol. LKI is Austria's second facility to adopt INTERCEPT for platelets. Combined with the General Hospital of Vienna, this means that around 12,000 platelet units, or 30% of the Austrian platelet market, could be treated with INTERCEPT. LKI's implementation of the INTERCEPT platelet system is anticipated to begin this month.

    Supplying around 10,000 platelet units yearly, ZIT Hamburg is the largest in-house blood component supplier to the Asklepios Group, which is one of Germany's three largest operators of private hospitals. ZIT Hamurg's implementation of INTERCEPT is anticipated to occur upon its receipt of regulatory approval from the Paul-Ehrlich-Institut to begin producing INTERCEPT-treated platelets.

    "Considering the inherent limitations and increasing cost of the current testing strategies used for platelets, we believe the INTERCEPT Blood System for platelets offers a strong value proposition that combines patient safety with commercial benefits," said ZIT Hamburg CEO O. Schertges.

    "We believe the breadth of clinical and routine-use data for INTERCEPT platelets accumulated over the last 10 years may have positively influenced the decisions made by LKI and ZIT Hamburg," said Cerus President and CEO William "Obi" Greenman. "It is this clinical experience and hemovigilance data that led to FDA's recent agreement to allow Cerus to proceed with a modular PMA submission for INTERCEPT platelets, without the need to conduct another prospective clinical trial."

    For more information about the INTERCEPT Blood System, visit www.cerus.com

    Sign up for "The Mission Report" at www.MissionIR.com

    Stocks: CERS
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.